-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $109

Benzinga·02/17/2026 15:54:12
Listen to the news
Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $112 to $109.